Composition
Each tablet contains:
Amlodipine (as besylate) ................................................................................... 5 or 10 mg
Inactive ingredients: Microcrystalline cellulose, calcium phosphate dibasic anhydrous, sodium starch glycolate, colloidal silicon dioxide, magnesium stearate.

Therapeutic Indications
Hypertension:
REGCOR tablets are indicated for the treatment of hypertension. They may be used alone or in combination with other antihypertensive agents.
Coronary Artery Disease (CAD):
Chronic Stable Angina:
REGCOR tablets are indicated for the symptomatic treatment of chronic stable angina. They may be used alone or in combination with other antianginal agents.
Vasospastic Angina (Prinzmetal’s or Variant Angina):
REGCOR tablets are indicated for the treatment of confirmed or suspected vasospastic angina. They may be used as monotherapy or in combination with other antianginal agents.
Angiographically Documented CAD:
In patients with recently documented CAD by angiography and without heart failure or an ejection fraction < 40%, REGCOR tablets are indicated to reduce the risk of hospitalization due to angina and to reduce the risk of a coronary revascularization procedure.

Dosage And Administration
Adults:
Hypertension:
The usual initial antihypertensive oral dose of REGCOR is 5 mg once daily with a maximum dose of 10 mg once daily.
Small, fragile, or elderly individuals, or patients with hepatic insufficiency may be started on 2.5 mg once daily and this dose may be used when adding REGCOR to other antihypertensive therapy.
Dosage should be adjusted according to each patient's need. In general, titration should proceed over 7-14 days so that the physician can fully assess the patient's response to each dose level. Titration may proceed more rapidly, however, if clinically warranted, provided the patient is assessed frequently.
Coronary Artery Disease (CAD):
Chronic stable or Vasospastic angina:
The recommended dose is 5-10 mg, with the lower dose suggested in the elderly and in patients with hepatic insufficiency.
Most patients will require 10 mg for adequate effect (see Undesirable Effects for Information related to dosage and side effects).
Children:
The effective antihypertensive oral dose in pediatric patients ages 6-17 years is 2.5 mg to 5 mg once daily. Doses in excess of 5 mg daily have not been studied in pediatric patients (see Pharmacological Properties).
Coadministration with other antihypertensive and/or Antianginal drugs:
REGCOR has been safely administered with thiazides, ACE inhibitors, beta-blockers, long-acting nitrates, and/or sublingual nitroglycerin.